Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102791 · ClinicalTrials.gov registry record · Phase 3
A Stratified Sickle Event Randomized Trial (ASSERT)
A Phase 3 study, sponsored by Icagen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 297
- Enrollment target
NCT00102791: Clinical Trial Phase 3 study, sponsored by Icagen.
NCT00102791 is a Phase 3 study that was terminated before completion, run by Icagen. The registered enrollment target is 297 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00102791, a Phase 3 study, was terminated before completion, sponsored by Icagen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 297 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects of ICA-17043 to placebo with or without hydroxyurea (an oral drug used for treatment of sickle cell disease) in patients with sickle cell disease who have had 2 or more acute sickle-related painful crises requiring a visit to a medical facility within the past 12 months.
Interventions
- DRUG ICA-17043
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Why NCT00102791 stopped before completion
NCT00102791 is an interventional study that assigns participants to a tested intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which ICA-17043 is the first listed.
NCT00102791 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00102791 about?
NCT00102791 is a clinical study titled "A Stratified Sickle Event Randomized Trial (ASSERT)". The purpose of this study is to compare the effects of ICA-17043 to placebo with or without hydroxyurea (an oral drug used for treatment of sickle cell disease) in patients with sickle cell disease who have had 2 or more acute sickle-related painful crises requiring a visit to a medical facility wit...
What is the current status of trial NCT00102791?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 297 participants. The study started on 2005-02. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00102791?
The interventions under investigation include: ICA-17043 (DRUG).
Who is sponsoring clinical trial NCT00102791?
This trial is sponsored by Icagen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00102791's enrollment target sits among peer trials
297 1163rd of 2000 higher than 837 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT06375811 · 297 participants · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
- NCT07222215 · 297 participants · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia